Tonix Pharmaceuticals Reports Q1 2026 Results, TONMYA Gains Traction with Managed Care Deal

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported first-quarter 2026 financial results on Wednesday, underscoring continued commercial momentum for TONMYA, its recently launched fibromyalgia treatment, and advancements across its clinical pipeline. The company noted that TONMYA, the first new fibromyalgia medicine in 15 years, has shown growth in prescriptions, prescribers, refills and patient access since its November 2025 launch.

A key highlight was a recently announced managed care agreement that expands potential coverage for TONMYA to approximately 35 million U.S. commercial lives. This deal could significantly boost patient access and prescription volumes, positioning TONMYA as a major player in the fibromyalgia market. The company’s commercial infrastructure, which also supports its acute migraine products Zembrace SymTouch and Tosymra, is being leveraged to maximize TONMYA’s reach.

On the pipeline front, Tonix reported positive Phase 1 data for TNX-4800, a monoclonal antibody candidate for Lyme disease prophylaxis. This candidate addresses a significant unmet need, as Lyme disease affects hundreds of thousands of people annually in the United States. The company also plans to begin a Phase 2 study of TONMYA in major depressive disorder later this year, exploring the drug’s potential beyond fibromyalgia. Additionally, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder.

Tonix is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s immunology pipeline includes TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs underscore Tonix’s commitment to addressing diverse medical challenges.

The financial results come at a critical time for Tonix as it transitions from a development-stage company to a commercial entity. The success of TONMYA is pivotal for revenue generation, and the managed care agreement could provide a substantial boost. However, the company faces competition in the fibromyalgia space and must navigate pricing and reimbursement challenges.

For more information, visit the company’s newsroom at https://ibn.fm/TNXP.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Tonix Pharmaceuticals Reports Q1 2026 Results, TONMYA Gains Traction with Managed Care Deal.

The post Tonix Pharmaceuticals Reports Q1 2026 Results, TONMYA Gains Traction with Managed Care Deal appeared first on citybuzz.